Rigel Pharmaceuticals Settles Patent Litigation Over Tavalisse
Rigel said the litigation arose after Annora submitted an abbreviated new drug application to the
Rigel said the settlement allows Annora to be licensed to sell its generic version starting in Q2 2032 or earlier under certain conditions.
The settlement also ends all ongoing litigation between Rigel and Annora over Tavalisse patents in
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
© 1999-2025 Midnight Trader, Inc. All rights reserved.
close
Rigel Pharmaceuticals Settles Patent Litigation Over Tavalisse
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "
Your e-mail has been sent.
close
Your e-mail has been sent.
Related News
-
TSMC affirms commitment to Taiwan with new domestic fab amid overseas expansion
Reuters - 17 minutes ago
-
Goldman Sachs expects US Fed to deliver three rate cuts in 2025
Reuters - 33 minutes ago
-
Trump says TikTok sale deal to come before Saturday deadline
Reuters - 38 minutes ago
-
Make Europe Great Again trades are gaining traction
Reuters - 12:04 AM ET 3/31/2025
-
Analysis-For China and US Inc, Trump's trade war feels much worse this time
Reuters - 12:01 AM ET 3/31/2025
-
Australia's Domain Holdings to recommend CoStar's $1.8 billion buyout bid
Reuters - 10:44 PM ET 3/30/2025
-
Virgin Australia executives set to meet investors ahead of re-listing, says source
Reuters - 10:42 PM ET 3/30/2025
Content for this page, unless otherwise indicated with a Fidelity pyramid logo, is selected and published by Fidelity Interactive Content Services LLC ("FICS"), a Fidelity company. All Web pages published by FICS will contain this legend. FICS was established to present users with objective news, information, data and guidance on personal finance topics drawn from a diverse collection of sources including affiliated and non-affiliated financial services publications. Content selected and published by FICS drawn from affiliated Fidelity companies is labeled as such. FICS-selected content provided is not intended to provide tax, legal, insurance, or investment advice, and should not be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by any Fidelity entity or any third party. Quotes are delayed unless otherwise noted. FICS is owned by FMR LLC and is an affiliate of Fidelity Brokerage Services LLC. Terms of use for Third-Party Content and Research
These links are provided by Fidelity Brokerage Services LLC ("FBS") for educational and informational purposes only. FBS is responsible for the information contained in the links. FICS and FBS are separate but affiliated companies and FICS is not involved in the preparation or selection of these links, nor does it explicitly or implicitly endorse or approve information contained in the links.
Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.
